How should a patient with relapsed multiple myeloma who has progressed to therapy‑related acute myeloid leukemia be treated?

Treatment of Therapy-Related AML Following Relapsed Multiple Myeloma

Prioritize enrollment in a clinical trial, and if unavailable, pursue intensive AML-directed therapy with allogeneic hematopoietic stem cell transplantation (allo-HSCT) as the only potentially curative option, recognizing that prognosis remains very poor. 1, 2, 3

Initial Management Approach

Immediate Assessment and Treatment Priority

• Repeat mutational analysis and cytogenetic testing at the time of AML diagnosis, as clonal evolution is frequent and may reveal targetable mutations that differ from the original myeloma clone 3, 4
• Clinical trial enrollment should be the first priority for all patients with relapsed/refractory AML, given the dismal outcomes with standard approaches 1, 2, 3
• The development of therapy-related AML (t-AML) after multiple myeloma treatment, particularly following CAR-T therapy, carries an exceptionally poor prognosis even with aggressive intervention 5

Risk Stratification for Treatment Intensity

For fit patients with adequate performance status:

• Pursue intensive salvage chemotherapy followed by allo-HSCT if a complete remission can be achieved 1, 2, 3
• Standard intensive salvage regimens consist of anthracycline and high-dose cytarabine backbone 3
• Allo-HSCT remains the only potentially curative strategy for most patients with relapsed/refractory AML 2, 3

For patients unable to tolerate intensive therapy:

• Consider venetoclax-based combinations with hypomethylating agents (HMA) if not previously used, which achieve encouraging response rates 4
• Alternative options include HMA monotherapy, low-dose cytarabine (LDAC), or cytoreductive therapy with hydroxyurea 4
• The therapeutic goal shifts to prolonging life with acceptable quality of life rather than cure 4

Targeted Therapy Based on Molecular Profile

FLT3-Mutated AML

• Gilteritinib is FDA and EMA approved and shows superior results compared to intensive salvage regimens in FLT3-mutated relapsed/refractory AML 3, 4
• This represents a well-tolerated option that should be prioritized if FLT3 mutations are detected 4

IDH1/2-Mutated AML

• Ivosidenib (IDH1 inhibitor) and enasidenib (IDH2 inhibitor) are FDA-approved (not EMA-approved) for relapsed/refractory AML with respective mutations 3, 4
• These agents achieve response rates of 30-40% even in elderly and heavily pre-treated patients 4
• Both are well-tolerated options that should be recommended when mutations are present 4

Critical Considerations and Pitfalls

The Thalidomide Paradox Warning

• Exercise extreme caution with immunomodulatory agents in patients with concomitant myelodysplasia or t-AML 6
• Historical data demonstrates that thalidomide, while showing anti-myeloma activity, was associated with rapid progression of MDS clones to AML 6
• This suggests that suppressing the myeloma clone may eliminate inhibitory signals and stimulate leukemic clone proliferation 6

Post-CAR-T Therapy Considerations

• Therapy-related AML following CAR-T immunotherapy (particularly BCMA CAR-T) demonstrates very poor prognosis 5
• Even allo-HSCT may not salvage these patients, emphasizing the need for close long-term monitoring after CAR-T therapy 5

Transplant Timing and Approach

• Patients achieving complete remission prior to allo-HSCT have more favorable outcomes 3
• Salvage therapy is given to reduce leukemia burden before transplantation 2, 3
• For patients with good performance status, intensive therapy followed by cellular therapy (donor lymphocyte infusion or second HSCT) can be considered, though less than 20% survive 5 years 4

Supportive Care Considerations

For Patients Declining Blood Products

• Aminocaproic or tranexamic acid may be considered when platelet counts decrease below 30,000/mcL 1
• Iron, folate, and vitamin B12 supplementation should be considered for deficiencies 1
• Bed rest and supplemental oxygenation for severe anemia 1
• Important caveat: Good outcomes with these strategies alone are rare 1

Infection Prophylaxis

• Antifungal prophylaxis is recommended for patients receiving venetoclax with HMA or LDAC for relapsed/refractory AML 1

Treatment Algorithm Summary

1. Confirm diagnosis with repeat mutational and cytogenetic analysis
2. Assess fitness for intensive therapy based on performance status and comorbidities
3. Prioritize clinical trial enrollment if available
4. If fit and no trial available:
   • Use targeted therapy if FLT3 or IDH1/2 mutations present
   • Otherwise, intensive salvage chemotherapy
   • Proceed to allo-HSCT if complete remission achieved
5. If unfit:
   • Venetoclax + HMA combinations (if not previously used)
   • Alternative: HMA monotherapy, LDAC, or hydroxyurea
   • Focus on quality of life and symptom management

The prognosis for therapy-related AML following multiple myeloma remains extremely poor, with limited curative options outside of successful allo-HSCT in select patients 5, 2, 3.